Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Veracyte Inc
(NQ:
VCYT
)
21.82
+0.82 (+3.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Present at Upcoming Investor Conferences
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
May 11, 2022
On Wednesday, 807 companies reached new 52-week lows.
Via
Benzinga
Analyst Ratings for Veracyte
May 04, 2022
Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following analyst ratings:
Via
Benzinga
Recap: Veracyte Q4 Earnings
February 28, 2022
Veracyte (NASDAQ:VCYT) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte...
Via
Benzinga
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
May 16, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Earnings Perspective: Return On Capital Employed
May 13, 2022
Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million.
Via
Benzinga
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
May 12, 2022
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
May 12, 2022
From
Veracyte
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
May 05, 2022
During Thursday, 351 stocks hit new 52-week lows.
Via
Benzinga
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
May 04, 2022
From
Veracyte, Inc.
Via
Business Wire
Recap: Veracyte Q1 Earnings
May 03, 2022
Veracyte (NASDAQ:VCYT) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by...
Via
Benzinga
Veracyte Announces First Quarter 2022 Financial Results
May 03, 2022
From
Veracyte, Inc.
Via
Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Earnings Scheduled For May 3, 2022
May 03, 2022
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Via
Benzinga
Preview: Veracyte's Earnings
May 02, 2022
Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will...
Via
Benzinga
Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
May 02, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
April 28, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
April 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
April 19, 2022
From
Veracyte, Inc.
Via
Business Wire
10 Biggest Price Target Changes For Tuesday
March 01, 2022
Keybanc cut the price target on Workday, Inc. (NASDAQ: WDAY) from $345 to $312. Workday shares rose 5.7% to $242.00 in pre-market trading.
Via
Benzinga
Veracyte Appoints Annie McGuire as General Counsel
February 28, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
February 22, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
February 15, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer
February 14, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
February 08, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
January 31, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
January 24, 2022
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.